Why the study?
Procedural strokes remain a weakness of TAVR and data supporting the use of embolic protection devices to decrease post-TAVR strokes are conflicting.
Post-approval analysis reveals real-world adoption of cerebral embolic protection in transcatheter aortic valve replacement, highlighting strategies to reduce stroke risk.
Despite contemporary advances in transcatheter aortic valve replacement (TAVR), procedural strokes remain a weakness of the procedure. 1 Cerebral embolic protection devices (EPDs) emerged as a potential method to decrease the risk of post-TAVR strokes. However, data supporting the use of EPDs are conflicting. In the Cerebral Protection in TAVR trial, EPDs did not reduce the rate of post-TAVR stroke, although em-bolic debris was captured in 99% of filters. 2 However, observational data and pooled analyses have suggested a potential benefit of EPDs. 3,4 This study sought to evaluate the early post-US Food and Drug Administration approval experience with the Sentinel device (Boston Scientific), the only EPD available in the United States.
No takes yet. Share an insight, caveat, or question.
Alkhouli et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: